- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01881581
Safety and Immunogenicity of Recombinant HIV Vaccines for HIV/AIDS
A Phase I Double-Blind Study to Evaluate the Safety and Immunogenicity of HIV Prime/Boost Vaccine Using DNA and MVA for HIV-1/AIDS
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
HIV-infected patients treated with antiretroviral therapy for prolonged periods of time may show decreased levels of HIV-specific immune responses. In these patients, a prime-boost vaccine strategy may induce both humoral and cell-mediated immunity. The hypothesis of this study is that the vaccine strategy selected will be both safe and immunogenic in the patient population being tested.
Patients continue antiretroviral medications throughout the course of this study. Three groups of patients receive dose-escalation (0.5mg, 2mg or 4mg) intramuscular injections of DNA vaccine (D-GPEi) respectively, the other three groups of patients receive dose-escalation (3×10^7pfu, 1×10^8pfu or 3×10^8pfu) intradermal injections of MVA vaccine (M-GPE), two weeks post immunization of lower dose, if the vaccine is safe and well tolerant, the next dose of immunization will begin. After the maximum tolerated dose of DNA and MVA is identified, DNA prime/ MVA boosting will be tested in another two groups of patients. Lower or the maximum tolerated dose of D-GPEi was used at week 0 and 1, lower or the maximum tolerated dose of M-GPE was used at week 2 and 3, patients are monitored for safety 72 hours after each immunization. In addition, each patient records adverse events in a diary. Patients have regular physical exams, pregnancy tests, and blood drawn for virologic and immunologic assessments. The induction of HIV-specific responses will be measured.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Recruiting
- Beijing Ditan Hospital of Capital Medical University
-
Contact:
- Xingwang Li
- Phone Number: 15611973658
- Email: ditanlxw@yahoo.com.cn
-
Principal Investigator:
- Xingwang Li
-
Sub-Investigator:
- Rongmeng Jiang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Are willing to participate this study and available for follow-up for the duration of the study.
- Men and women aged 18-50 years.
- Are HIV-positive.
- Have been taking stable anti-HIV drugs for at least 6 months.
- CD4 count ≥ 350 cells/mm3
- Plasma viral load < 50 copies/ml.
- Willing to use acceptable forms of contraception at least 21 days prior to first vaccination until 56 days after the last vaccination.
Exclusion Criteria:
- Pregnancy or breast-feeding.
- History of previous vaccination with an HIV-1 vaccine.
- Use of immunoinhibitory agents, such as corticosteroids or cytotoxic drugs by oral administration, injection route or inhalation route within 6 months of study entry (But corticosteroids used for allergic rhinitis and skin topical application of corticosteroids were not included); Use of immunomodulatory agents including but not limited to interleukin-2(IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF) within 30 days of study entry.
- Use of blood products within 3 months of study entry.
- Use of other experimental drugs within 3 months of study entry.
- Any immunization within 3 months of study entry.
- Comply with any of the following items: Active pulmonary tuberculosis; History of serious adverse reaction to other vaccines; Serious asthma; Have untreated thyroid disease; Syphilis
- Laboratory values(Comply with any of the following items):
Hemoglobin < 100 g/L (male subjects),<90 g/L (female subjects); Absolute neutrophil count ≤ 1000 cells/mm3; Serum creatinine ≥15 mg/L,endogenous creatinine clearance rate <50 ml/min; alanine aminotransferase(ALT), aspartate aminotransferase(AST) ≥3× upper limit of normal range; Total bilirubin ≥2× upper limit of normal range
- Clinically significant electrocardiogram changes.
- Hypertension ( If it is well controlled by medication and is less than 150/100mmHg , should not be excluded) and other cardiac disease;
- Any medical, psychiatric, social condition, occupational reason judged by the investigator that would limit the evaluation of a subject.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lower dose DNA or Placebo
2.0 mL lower dose D-GPEi (0.5mg) or Saline solution at weeks 0
|
Saline Solution is used as control in all arms.
D-GPEi is used in Arm A,B,C,G and H.
|
Experimental: Medium dose DNA or Placebo
2.0 mL medium dose D-GPEi (2mg) or Saline solution at weeks 0
|
Saline Solution is used as control in all arms.
D-GPEi is used in Arm A,B,C,G and H.
|
Experimental: High dose DNA or Placebo
2.0 mL high dose D-GPEi (4mg) or Saline solution at weeks 0
|
Saline Solution is used as control in all arms.
D-GPEi is used in Arm A,B,C,G and H.
|
Experimental: Lower dose MVA or Placebo
100μL lower dose M-GPE (3×10^7pfu) or Saline solution at weeks 0
|
Saline Solution is used as control in all arms.
M-GPE is used in Arm D,E,F,G and H
|
Experimental: Medium dose MVA or Placebo
100μL medium dose M-GPE (1×10^8pfu) or Saline solution at weeks 0
|
Saline Solution is used as control in all arms.
M-GPE is used in Arm D,E,F,G and H
|
Experimental: High dose MVA or Placebo
300μL high dose M-GPE (3×10^8pfu) or Saline solution at weeks 0
|
Saline Solution is used as control in all arms.
M-GPE is used in Arm D,E,F,G and H
|
Experimental: Low dose DNA+MVA or Placebo control
The dose below the maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1; The dose below the maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
|
Saline Solution is used as control in all arms.
D-GPEi is used in Arm A,B,C,G and H.
M-GPE is used in Arm D,E,F,G and H
|
Experimental: High dose DNA+MVA or Placebo control
The maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1;The maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
|
Saline Solution is used as control in all arms.
D-GPEi is used in Arm A,B,C,G and H.
M-GPE is used in Arm D,E,F,G and H
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence, intensity and relationship to vaccination of local and systemic adverse events
Time Frame: 8 months
|
To evaluate the safety and tolerance of a DNA and a replication-defective MVA vaccine expressing HIV-1 gag-pol and env in HIV-1 infected subjects on highly active antiretroviral therapy. Frequency and severity of adverse events, laboratory abnormalities, and local and systemic reactogenicity signs and symptoms following vaccinations |
8 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity of vaccine
Time Frame: 14 months
|
Changes in CD4+ and CD8+ T-cell counts pre- and post-immunization and between the vaccine and placebo groups Changes in viral load pre- and post-immunization and between the vaccine and placebo groups Magnitude and breadth of HIV-1 specific CD8+ T cell responses as determined by interferon-γ(IFN-γ) enzyme-linked immunospot (ELISPOT) using overlapping HIV peptides for gag, pol and env Changes in HIV-1 Gp160-specific antibody responses pre- and post-immunization and between the vaccine and placebo groups
|
14 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ke Xu, Ph.D, National Institute for Viral Disease Control and Prevention, China CDC
- Principal Investigator: Xingwang Li, M.D., Beijng Ditan Hospital of Capital Medical University
- Principal Investigator: Rongmeng Jiang, M.D., Beijng Ditan Hospital of Capital Medical University
- Principal Investigator: Yi Zeng, National Institute for Viral Disease Control and Prevention, China CDC
- Principal Investigator: Xia Feng, Ph.D, National Institute for Viral Disease Control and Prevention, China CDC
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
Other Study ID Numbers
- CDCPChina001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acquired Immunodeficiency Syndrome
-
VA Eastern Colorado Health Care SystemPublic Health Grant Program, Veterans Health Administration Office of Public...CompletedHuman Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) | Self-Directed ViolenceUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus | Acquired Immune Deficiency Syndrome Virus | Acquired Immunodeficiency Syndrome Virus | AIDS Virus | Human Immunodeficiency VirusesUnited States
-
Columbia UniversityNational Institute of Mental Health (NIMH); Ministry of Health and Social Welfare...CompletedHIV (Human Immunodeficiency Virus) | AIDS (Acquired Immunodeficiency Syndrome)Tanzania
-
Janssen-Cilag International NVCompletedHIV Infections | Human Immunodeficiency Virus | Acquired Immunodeficiency Syndrome Virus | AIDS VirusUnited Kingdom, Belgium, Germany, Spain, Portugal, Israel, Denmark, Russian Federation, Austria, Hungary, Switzerland
-
Emory UniversityGrady Health SystemCompleted
-
Columbia UniversityNational Institute of Nursing Research (NINR)CompletedHIV (Human Immunodeficiency Virus) | AIDS (Acquired Immunodeficiency Syndrome)United States
-
St. Jude Children's Research HospitalCompletedHuman Immunodeficiency Virus (HIV) | Acquired Immunodeficiency Syndrome (AIDS)United States
-
Janssen-Cilag International NVCompletedHuman Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) VirusFrance, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
-
Columbia UniversityNational Institute of Mental Health (NIMH)CompletedHuman Immunodeficiency Virus (HIV) | Acquired Immune Deficiency Syndrome (AIDS)Ethiopia
-
Columbia UniversityCenters for Disease Control and PreventionCompletedHuman Immunodeficiency Virus (HIV) | Acquired Immune Deficiency Syndrome (AIDS)South Africa
Clinical Trials on Saline Solution
-
Chiang Mai UniversityCompletedPostoperative Nausea and Vomiting
-
Hospital Clinic of BarcelonaCompletedBronchiectasisSpain
-
Laval UniversityCanadian Institutes of Health Research (CIHR); Centre de Recheche du Centre...WithdrawnAcute Viral Bronchiolitis.Canada
-
Rabin Medical CenterUnknown
-
George Washington UniversityCompletedHysterectomy | MyomectomyUnited States
-
Federal University of Minas GeraisNot yet recruitingAnesthesia, ConductionBrazil
-
Assistance Publique - Hôpitaux de ParisCompletedAcute Viral BronchiolitisFrance
-
Children's Hospital of PhiladelphiaCompletedSaline Solution, Hypertonic | Bronchiolitis, ViralUnited States
-
Stefania La Grutta, MDCompleted
-
Universidad Autonoma de Baja CaliforniaCompleted